State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR

Key Points

• State of New Jersey Common Pension Fund D bought a new position of 33,538 shares of Kymera Therapeutics in Q4, valued at approximately $2.61 million.
• Insiders sold 380,734 shares (about $32.19 million) in the last quarter — notable transactions include Noah Goodman (8,264 shares sold under a Rule 10b5‑1 plan) and COO Jeremy G. Chadwick (91,250 shares) — while company insiders still own 16.01% of the stock.
• Kymera beat quarterly expectations with revenue of $34.37M (vs. $8.27M expected) and EPS -$0.71 (vs. -$0.89 expected); analysts have a consensus rating of "Moderate Buy" and a $118.10 average price target.

State of New Jersey Common Pension Fund D bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 33,538 shares of the company's stock, valued at approximately $2,610,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Holocene Advisors LP bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth approximately $47,563,000. Commodore Capital LP bought a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $32,730,000. Alyeska Investment Group L.P. lifted its holdings in shares of Kymera Therapeutics by 1,130.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company's stock worth $34,814,000 after purchasing an additional 565,091 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth approximately $31,622,000.

Insider Activity at Kymera Therapeutics

In other news, insider Noah Goodman sold 8,264 shares of Kymera Therapeutics stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00. Following the transaction, the insider directly owned 53,542 shares in the company, valued at approximately $4,684,925. This trade represents a 13.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jeremy G. Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief operating officer owned 61,202 shares in the company, valued at approximately $4,737,646.82. This trade represents a 59.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 380,734 shares of company stock worth $32,193,902 in the last quarter. Company insiders own 16.01% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KYMR. Piper Sandler raised their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, February 26th. Canaccord Genuity Group began coverage on Kymera Therapeutics in a report on Wednesday. They issued a "buy" rating and a $106.00 price target on the stock. Morgan Stanley restated an "overweight" rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Barclays raised their target price on Kymera Therapeutics to $133.00 and gave the company an "overweight" rating in a research report on Tuesday, January 27th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $118.10.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Canaccord Genuity initiated coverage with a "Buy" rating and a $106 price target (roughly mid‑teens upside vs. current levels), which can attract new buyers and raise investor visibility. Canaccord Coverage
• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts (Q2–Q4 2026 and FY2026) and lifted mid‑range year estimates (FY2027–FY2028), signaling improving analyst expectations for cash flow trajectory and program progress. This upgrade momentum supports sentiment. HC Wainwright Note
• Positive Sentiment: Kymera presented new preclinical IBD data for KT‑579 at Digestive Disease Week showing activity comparable or superior to approved/clinically active therapies — a potentially material data point for the IRF5 degrader program's clinical prospects. KT-579 Preclinical Data
• Neutral Sentiment: Kymera will participate in multiple investor conferences this month (fireside chats) — increases management access to investors but is informational rather than catalytic by itself. Investor Conferences
• Negative Sentiment: Some analyst notes trimmed longer‑term estimates: HC Wainwright lowered FY2030 EPS (from $1.34 to $1.07) and made small adjustments to FY2029 — these cuts temper late‑cycle upside expectations and highlight forecasting uncertainty for commercialization/timing. Longer‑Term Estimate Changes

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $86.26 on Thursday. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00. The stock has a market cap of $7.10 billion, a PE ratio of -24.16 and a beta of 2.06. The business's fifty day moving average is $84.38 and its 200-day moving average is $76.79.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. During the same period last year, the firm earned ($0.82) EPS. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. Equities research analysts predict that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.